Physician profile
Augustin Delago
NPI 1114911633
$1,844,952.99
in general payments reported to CMS, 2019-2025
39 companies · $318K in 2025
The $318K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198K · 2020: $193K · 2021: $312K · 2022: $218K · 2023: $259K · 2024: $347K · 2025: $318K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $550K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $331K · Travel and Lodging: $24K · Food and Beverage: $19K · Education: $68.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $550,412.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $330,537.50 |
| Travel and Lodging | $23,762.29 |
| Food and Beverage | $18,887.71 |
| Education | $68.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,157,022.27 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Evoque |
| Boston Scientific Corporation | $574,170.66 | 2019-2025 | Versacross Access Solution, Sentinel, Versacross Large Access Solution |
| Baylis Medical Company INC | $69,312.63 | 2019-2021 | |
| Abbott Laboratories | $32,227.41 | 2019-2025 | Mitraclip, Aveir, Navitor |
| Siemens Medical Solutions USA, INC. | $4,175.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,197.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $899.83 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $812.12 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $754.63 | 2019-2025 | |
| Chiesi USA, INC. | $572.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $424.90 | 2019-2023 | Xarelto |
| Abiomed | $395.51 | 2019-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $347.63 | 2019-2024 | Farxiga |
| Aop Health US, LLC | $326.40 | 2025 | Rapiblyk |
| Angiodynamics, INC. | $301.75 | 2023 | Angiovac, Auryon Laser System 100-120 Vac |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustin Delago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.